BRCA mutation testing in determining breast cancer therapy

Karen Lisa Smith, Claudine Isaacs

Research output: Contribution to journalReview articlepeer-review

Abstract

BRCA mutation-associated breast cancer differs from sporadic breast cancer with regard to future cancer risks and sensitivity to systemic therapies. Now that rapid genetic testing for BRCA1 and BRCA2 mutations is available at the time of breast cancer diagnosis, BRCA mutation status can be considered when making treatment and prevention decisions for BRCA mutation carriers with breast cancer. This article reviews surgical options for management of affected BRCA mutation carriers with emphasis on the risks of ipsilateral recurrence and contralateral breast cancer. The roles of breast-conserving surgery, prophylactic mastectomy, and oophorectomy are reviewed. In addition, the sensitivity of BRCA mutation-associated breast cancer to endocrine therapy, platinum chemotherapy, and poly (ADP-ribose) polymerase inhibitors is reviewed.

Original languageEnglish (US)
Pages (from-to)492-499
Number of pages8
JournalCancer Journal
Volume17
Issue number6
DOIs
StatePublished - Nov 2011
Externally publishedYes

Keywords

  • BRCA1
  • BRCA2
  • breast cancer

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'BRCA mutation testing in determining breast cancer therapy'. Together they form a unique fingerprint.

Cite this